Upstream Bio (UPB) News
NASDAQ: UPBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.59-0.41 (-20.50%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
UPB news summary
We found 2 recent headlines mentioning Upstream Bio (UPB): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. UPB is making an outsized move today, down 20.50% at $1.59, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Upstream Q3 Loss Widens On Higher R&D Costs; Two Phase 2 Verekitug Readouts Due In H2 2027", was published by Nasdaq on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Upstream Bio headlines
- Upstream Q3 Loss Widens On Higher R&D Costs; Two Phase 2 Verekitug Readouts Due In H2 2027(RTTNews) - Upstream Bio, Inc. (UPB) released third-quarter financial results, reflecting wider loss than a year earlier as operating expenses increased. The company provided several clinical updates.NasdaqUPB, HEI.A
- Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress– Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 –GlobeNewswire